Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Subscribe To Our Newsletter & Stay Updated